Topical imiquimod.
In this ever-expanding world of immunologic advancements, Drs Langley and Pearson have undertaken this timely, succinct review of imiquimod. Given its direct actions on monocytes and macrophages, as well as the many diverse cytokine effects that follow from these events, topical imiquimod has already solidly established itself as a successful treatment for condylomata and molluscum, and will likely show continued therapeutic applications in the future.
Pearson
G W
GW
Massachusetts General Hospital, Harvard Medical School, Dermatology Clinical Investigations Unit, Cambridge St, MA, Boston, USA.
Langley
R G
RG
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D000287:Administration, Topical; D000634:Aminoquinolines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D003218:Condylomata Acuminata / Q000188:drug therapy*; D006801:Humans; D000077271:Imiquimod; D009824:Ointments
D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D009824:Ointments; D000077271:Imiquimod